Key Points
- Insider sale: Gregory Odle sold 8,433 shares on March 16 at $17.25 for $145,469.25, reducing his holding to 187,735 shares (a 4.3% decline).
- Multiple senior insiders sold too: The CEO, CFO, general counsel and other executives also sold shares at about $17.25 in the same period, each cutting their stakes by roughly 4–6%.
- Company context: OrthoPediatrics trades near $17.2 with a market cap of ~$435M; it reported a quarterly EPS beat (-$0.26 vs. -$0.37) and slight revenue upside but remains unprofitable with a negative P/E and a 12-month range of $15.28–$26.40.
OrthoPediatrics Corp. (NASDAQ:KIDS - Get Free Report) insider Gregory Odle sold 8,433 shares of the company's stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $17.25, for a total transaction of $145,469.25. Following the transaction, the insider owned 187,735 shares in the company, valued at $3,238,428.75. The trade was a 4.30% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
OrthoPediatrics Trading Up 0.6%
NASDAQ:KIDS opened at $17.21 on Wednesday. OrthoPediatrics Corp. has a 12 month low of $15.28 and a 12 month high of $26.40. The firm has a fifty day simple moving average of $17.71 and a 200-day simple moving average of $17.94. The company has a current ratio of 5.55, a quick ratio of 2.65 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $435.07 million, a P/E ratio of -10.18 and a beta of 1.07.
OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last released its earnings results on Thursday, February 26th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.11. The firm had revenue of $61.61 million for the quarter, compared to the consensus estimate of $61.27 million. OrthoPediatrics had a negative return on equity of 6.70% and a negative net margin of 16.77%. On average, equities research analysts anticipate that OrthoPediatrics Corp. will post -0.93 earnings per share for the current year.
Hedge Funds Weigh In On OrthoPediatrics
Institutional investors and hedge funds have recently modified their holdings of the stock. Russell Investments Group Ltd. boosted its stake in shares of OrthoPediatrics by 433.1% in the third quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company's stock worth $26,000 after buying an additional 1,139 shares during the last quarter. Northwestern Mutual Wealth Management Co. grew its holdings in OrthoPediatrics by 5,226.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company's stock worth $46,000 after acquiring an additional 2,561 shares during the period. Caption Management LLC purchased a new position in OrthoPediatrics during the third quarter valued at approximately $54,000. BNP Paribas Financial Markets raised its position in OrthoPediatrics by 60.2% during the third quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company's stock valued at $61,000 after acquiring an additional 1,235 shares in the last quarter. Finally, State of Wyoming lifted its holdings in OrthoPediatrics by 189.7% in the fourth quarter. State of Wyoming now owns 6,822 shares of the company's stock valued at $121,000 after acquiring an additional 4,467 shares during the period. Institutional investors and hedge funds own 69.05% of the company's stock.
Analyst Upgrades and Downgrades
Several research analysts have recently issued reports on the company. BTIG Research raised their price objective on OrthoPediatrics from $23.00 to $24.00 and gave the stock a "buy" rating in a research note on Friday, February 27th. Needham & Company LLC upped their target price on OrthoPediatrics from $26.00 to $30.00 and gave the company a "buy" rating in a research report on Friday, February 27th. TD Cowen upgraded shares of OrthoPediatrics to a "strong-buy" rating in a report on Tuesday, January 27th. Weiss Ratings reissued a "sell (e+)" rating on shares of OrthoPediatrics in a research report on Thursday, January 22nd. Finally, Wall Street Zen upgraded shares of OrthoPediatrics from a "sell" rating to a "hold" rating in a research note on Saturday, March 7th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, OrthoPediatrics currently has an average rating of "Moderate Buy" and a consensus target price of $24.67.
Check Out Our Latest Stock Report on KIDS
OrthoPediatrics News Roundup
Here are the key news stories impacting OrthoPediatrics this week:
- Negative Sentiment: CEO David R. Bailey sold 19,535 shares at an average price of $17.25 (≈$336,979); his direct stake fell ~6.15% to 298,020 shares. SEC Filing
- Negative Sentiment: CFO Fred Hite sold 12,993 shares at $17.25 (≈$224,129); his holding decreased ~4.47% to 277,477 shares. SEC Filing
- Negative Sentiment: General Counsel Daniel J. Gerritzen sold 8,614 shares at $17.25 (≈$148,592); his stake fell ~5.45% to 149,533 shares. SEC Filing
- Negative Sentiment: Insider Gregory A. Odle sold 8,433 shares at $17.25 (≈$145,469); his position declined ~4.30% to 187,735 shares. SEC Filing
- Negative Sentiment: Insider Joseph W. Hauser sold 8,596 shares at $17.25 (≈$148,281); his stake fell ~4.23% to 194,767 shares. SEC Filing
OrthoPediatrics Company Profile
(
Get Free Report)
OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.
The company's product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
